Neuroendocrine Tumors: all 682 studies
Page 4 of 7. Open to participants first (163), then studies with results posted, then the rest; newest registration first within each.
- A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver MetastasesCompletedNCT06853457
- Efficacy of Endoscopic Band Ligation (DEBL) for Duodenal Neuroendocrine Neoplasms(dNENs)CompletedNCT06790056
- The Role of Intraoperative Hepatic Ultrasonography in Gastrointestinal or Pancreatic Neuroendocrine TumorCompletedNCT06779708
- Agnostic Therapy in Rare Solid TumorsActive, not recruitingNCT06638931Phase 2
- Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor MalignanciesActive, not recruitingNCT06577987Phase 1
- Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly PatientsCompletedNCT06570174Not applicable
- Pancreatic Fistula After Minimally Invasive EnucleationCompletedNCT06557408
- Defining Response Criteria for PET Scans for People With Neuroendocrine TumorsActive, not recruitingNCT06448208
- EchoTip AcuCore Post-Market Clinical StudyCompletedNCT06358001
- A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and AcromegalyCompletedNCT06253897
- A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETsActive, not recruitingNCT06232564Phase 2
- Clinical Application of the Prototype J-PET DeviceCompletedNCT06211803
- Lipiodol Deposition Using Endhole vs. Pressure-Modulated DeliveryActive, not recruitingNCT06204159Not applicable
- Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRTCompletedNCT06183047
- 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine TumoursCompletedNCT06155994Phase 1/2
- A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine TumorsActive, not recruitingNCT06148636Early Phase 1
- Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine TumorsCompletedNCT06143605
- Using Novel Imaging to More Safely Treat Neuroendocrine TumorsCompletedNCT06122610Phase 1
- Real-world Study on Adjuvant Octreotide Therapy in pNETsCompletedNCT06080204Not applicable
- A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell TherapyActive, not recruitingNCT06055439Phase 1/2
- Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or ReconstructionCompletedNCT06024343Not applicable
- Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver MetastasesTerminatedNCT05987176Phase 2
- A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NETTerminatedNCT05922579
- A Study of PM8002 in Combination With Chemotherapy in Patients With NENActive, not recruitingNCT05879055Phase 2
- Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine NeoplasmsCompletedNCT05871320Early Phase 1
- Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)CompletedNCT05816720
- A Bioequivalence Study of Sunitinib Malate Capsules.CompletedNCT05800106Phase 1
- Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine TumorsActive, not recruitingNCT05724108Phase 2
- GastroIntestinal Cancer in Children and AdolescentsStatus unknownNCT05693519
- Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard ChemotherapyStatus unknownNCT05627427Phase 2
- Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the LiverWithdrawnNCT05610826Phase 1/2
- Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable CancersWithdrawnNCT05582031Phase 2
- Neoadjuvant PRRT With Y-90-DOTATOC in pNETTerminatedNCT05568017Phase 2
- A Real-world Comparison of FNB and FNA in IHC-required Lesions.CompletedNCT05565066
- F-Tryptophan PET/CT in Human CancersCompletedNCT05556473Phase 1
- Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors.CompletedNCT05528614
- Biomarker Identification of Radionuclide Therapy-induced Radiation ResponsesStatus unknownNCT05513469Not applicable
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingNCT05477576Phase 3
- Artificial Intelligence in EUS for Diagnosing Pancreatic Solid LesionsCompletedNCT05476978
- 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine TumorsCompletedNCT05475210Phase 1
- A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETsActive, not recruitingNCT05459844Phase 3
- 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NETActive, not recruitingNCT05448157
- HRQoL During PRRT in Patients With NETsCompletedNCT05427032
- Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine TumorsActive, not recruitingNCT05255159Phase 2
- A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA TreatmentCompletedNCT05255133Not applicable
- Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine TumorsActive, not recruitingNCT05249114Phase 1
- Preoperative Imaging in Patients With Small Bowel Neuroendocrine TumorsCompletedNCT05246319
- Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and CarcinomasStatus unknownNCT05234450
- A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid MalignanciesActive, not recruitingNCT05199272Phase 1/2
- Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/BiopsyCompletedNCT05171517
- Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine TumorsCompletedNCT05168631
- HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors StudyActive, not recruitingNCT05167071Phase 1
- Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor PatientsActive, not recruitingNCT05153772Phase 2
- Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine NeoplasmStatus unknownNCT05113355Phase 2
- Open-label Study of Surufatinib in Japanese PatientsCompletedNCT05077384Phase 1/2
- Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine CarcinomaStatus unknownNCT05076786Phase 2
- Neuroendocrine Tumors - Patient Reported OutcomesActive, not recruitingNCT05064150
- A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072CompletedNCT05017662Not applicable
- Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-studyCompletedNCT05013957
- Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic CancerCompletedNCT04977596
- Combination Immunotherapy in Rare Cancers Under InvesTigationActive, not recruitingNCT04969887Phase 2
- Neuroendocrine Neoplasm Based on Multi-omics Integrated AnalysisStatus unknownNCT04931446
- Single-cell Sequencing and Establishment of Models in Neuroendocrine NeoplasmStatus unknownNCT04927611
- Optimising Molecular Radionuclide TherapyCompletedNCT04922801
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEActive, not recruitingNCT04919226Phase 3
- 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsWithdrawnNCT04915144Phase 2
- Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine TumorsStatus unknownNCT04897542Early Phase 1
- A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine TumorsTerminatedNCT04893759Phase 1
- Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine TumorsWithdrawnNCT04831567Phase 2
- Expanded Access Program of SurufatinibNo longer availableNCT04814732
- Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine TumorsActive, not recruitingNCT04804371Not applicable
- Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)Status unknownNCT04790708Not applicable
- Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization AnalysisCompletedNCT04780737
- Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid SyndromeWithdrawnNCT04776876Phase 2
- Ki67 Proliferation Index of Pancreatic Neuroendocrine NeoplasiaCompletedNCT04753229
- Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsActive, not recruitingNCT04750954Phase 1
- Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETsCompletedNCT04727723
- Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)Status unknownNCT04720391
- Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat EthylWithdrawnNCT04713202Phase 2
- Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETsCompletedNCT04696042
- Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine TumorsWithdrawnNCT04672876Phase 2
- United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration SettingCompletedNCT04649580
- Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRTStatus unknownNCT04622631
- A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine TumorsWithdrawnNCT04614766Phase 1/2
- Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsActive, not recruitingNCT04584008Not applicable
- Fatigue and Quality of Life in Patients With Neuroendocrine NeoplasiaStatus unknownNCT04557137
- Al18F-NOTA-octreotide PET Imaging in Neuroendocrine TumorsCompletedNCT04552847Phase 2/3
- Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the LiverActive, not recruitingNCT04544098Early Phase 1
- A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine TumoursStatus unknownNCT04525638Phase 2
- A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3Active, not recruitingNCT04524208Phase 2
- Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine TumorsCompletedNCT04510311Early Phase 1
- Impact of Peptides and Chelators on Somatostatin Receptor AntagonistsStatus unknownNCT04491851Phase 2
- Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)sTerminatedNCT04488263
- Nutrition in Gastrointestinal TumorsCompletedNCT04476082
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingNCT04471727Phase 1/2
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various CancersActive, not recruitingNCT04459273Phase 1
- CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive HypoglycaemiaTerminatedNCT04452396Not applicable
- An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine TumoursCompletedNCT04440956Early Phase 1
- A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)CompletedNCT04438304Phase 2
- Neuroendocrine and Adrenal TumorsWithdrawnNCT04432532